IL5 and nasal cavity polyp: Approved biological therapies for nasal polyps include omalizumab, [a monoclonal antibody to immunoglobulin E (IgE)], mepolizumab [a monoclonal antibody to interleukin-5 (IL-5)], and dupilumab [a monoclonal antibody to the IL-4 receptor alpha subunit, blocking IL-4 and IL-13 activity].